2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, (CAR)-T Cell Therapies, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Genomics, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Thrombocytopenias, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, Research, APL, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Pregnant, Animal Model
PAPER

1298 Clinical phenotypes and genetic spectrum in women with congenital factor VII deficiency: A multicenter real-world cohort study

Nating Cai, Zhuo-Yu An, MD2, Ying Feng3, Yi Chen4, Yunhai Fang5, Lei Zhang, MD6, JUN Peng Sr, MD7, Shuqian Xu8, Jinhai Ren, MD9, Puhui Zhou10, Lan Zhu11, Xu Yang, PhD12, Dong Lai13, Jun Luo, DO14, Hehe Wang15, Hai-Xia Fu, MD16, Yuanyuan Zhang17, Qiusha Huang18, Jin Wu19, Peng Zhao20, Xiaolu Zhu, MD21, Yun He, MD22, Li-Ping Yang23, Chen-Cong Wang24, Qi Chen25, Xiaohui Zhang, MD26
1 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
2 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
3 Department of Hematology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
4 Department of Hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
5 Shandong Blood Center, Shandong Hemophilia Treatment Center, Jinan, China
6 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
7 Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
8 Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
9 Hematology Institute of Hebei Province, Second Hospital of Hebei Medical University, Shijiazhuang, China
10 Department of Medical Laboratory, First Affiliated Hospital of Nanchang University, Nanchang, China
11 Department of Obstetrics and Gynecology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
12 Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China
13 Department of Hematology, the Second Affiliated Hospital of Xiamen Medical College, Xiamen, China
14 Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, Guangxi, China
15 Shandong Blood Center, Shandong Hemophilia Treatment Center, Jinan, China
16 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
17 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
18 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
19 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
20 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
21 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
22 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
23 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
24 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
25 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China
26 1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China 2. National Clinical Research Center for Hematologic Disease, Beijing, China 3. Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 4. Collaborative Innovation Center of Hematology, Peking University Institute of Hematology, Beijing, China, Beijing, China

Introduction

Congenital factor VII (FVII) deficiency is the most common rare congenital coagulation disorder, posing significant hemostatic challenges for pregnant women. However, there are three major knowledge gaps in this area. First, it is unclear whether the discrepancies among bleeding severity, FVII coagulant activity (FVII: C), and F7 genotypes seen in other populations apply to Chinese women with this condition. Second, the independent risk factors for postpartum hemorrhage (PPH) in pregnant women with congenital FVII deficiency have yet to be comprehensively explored. Third, the spectrum of F7 mutations associated with this disorder in the Chinese female population has not been systematically characterized. Therefore, this study aims to address these gaps by characterizing the clinical bleeding phenotypes and F7 mutation spectrum of Chinese women with congenital FVII deficiency, identifying independent risk factors for PPH in this group, and investigating the correlation between genotype and phenotype of the disease.

Methods

In this nationwide multicenter retrospective cohort study, 91 female patients diagnosed with congenital FVII deficiency across 12 tertiary hospitals in China whose demographic characteristics, obstetric history, and laboratory testing data were collected for subsequent analysis were included. F7 variants were identified by next-generation sequencing with reference sequence NM_000131.4, following HGVS guidelines for variant naming. FVII: C levels were stratified in accordance with the classification criteria of Quintavalle et al. (≤10%, 10%-25%, 25%-50%) and the clinical manifestation classification criteria of Mariani et al. (asymptomatic, mild, moderate, or severe). Univariable logistic regression was performed to screen for potential predictors of PPH among the 11 candidate variables; those with P values < 0.2 were subsequently entered into a multivariate logistic regression model.

Results

Among 91 women, 50.5% of patients had at least one lifetime bleeding event in which menorrhagia (27%) was most frequent. The mean FVII: C did not differ significantly across the 4 severity groups (P > 0.05), and women with an FVII ≤10% could be asymptomatic or have mild bleeding. PPH occurred in 27.7% of the 47 available pregnancies. Univariable screening and multivariable logistic regression revealed that delivery age (OR 1.530; 95% CI, 1.068–2.192; P = 0.021), personal bleeding history (OR 7.435; 95% CI, 1.083–51.034; P = 0.041), cesarean delivery (OR 16.398; 95% CI, 1.544–174.170; P = 0.020), and third-trimester FVII: C <20% (OR 33.638; 95% CI, 1.633–692.863; P = 0.023) were significantly associated with PPH. Among 37 patients with F7 mutations, 33 distinct pathogenic variants were identified; 60.6% were missense and 11 were unrecorded in the EAHAD FVII variant database or ClinVar. Variants were distributed uniformly along F7, and most missense mutations were clustered in the serine protease domain. Two recurrent mutations were detected including the missense mutation c.1158T>G (p.H386Q) and the splice-site variant c.615+1G>T. No significant difference in baseline FVII: C or PPH incidence was found across variants in different F7 domains (all P > 0.05). The distribution of bleeding severity differed significantly (H = 10.876; P = 0.003) in which heterozygotes had milder bleeding and homozygotes had more severe bleeding (adjusted P = 0.003). No significant difference was found between the compound heterozygous group and the other two groups. The Kruskal-Wallis H test found no significant between-group difference in the overall FVII: C distribution (H = 2.828; P = 0.243). The median FVII: C was descriptively higher in heterozygotes (27.40%) than in homozygotes (3.71%), with no statistically significant difference.

Conclusions

This multicenter real-world study delineated the clinical and genetic spectrum of congenital FVII deficiency in Chinese women. This study identified four independent PPH predictors that differed from those in the current guidelines in terms of FVII: C and bleeding history: advanced delivery age, personal bleeding history, cesarean delivery, and third-trimester FVII: C <20%. Genetic mapping revealed that the serine protease domain is the mutation hotspot and that missense mutations are the predominant variant. These findings lay a preliminary foundation for future studies on individualized management that integrate laboratory values, clinical risk factors and genetic information.

Nating Cai: No relevant conflicts of interest to declare.